Greenwich Historical Financial Ratios
| GLSI Stock | USD 14.25 0.32 2.20% |
Greenwich Lifesciences is recently reporting on over 78 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 21.18 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Greenwich Lifesciences financial condition quickly.
Greenwich |
About Greenwich Financial Ratios Analysis
Greenwich LifesciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Greenwich Lifesciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Greenwich financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Greenwich Lifesciences history.
Greenwich Lifesciences Financial Ratios Chart
Add Fundamental
Operating Cash Flow Per Share
A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Greenwich Lifesciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Greenwich Lifesciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.As of now, Greenwich Lifesciences' Cash Per Share is increasing as compared to previous years. The Greenwich Lifesciences' current Price Book Value Ratio is estimated to increase to 21.18, while Book Value Per Share is projected to decrease to 0.47.
Greenwich Lifesciences fundamentals Correlations
Click cells to compare fundamentals
Greenwich Lifesciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Greenwich Lifesciences fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (43.48) | 16.77 | 11.74 | 14.85 | 20.17 | 21.18 | |
| Book Value Per Share | (0.11) | 2.18 | 2.07 | 1.02 | 0.52 | 0.47 | |
| Free Cash Flow Yield | (0.004995) | (0.002489) | (0.0136) | (0.0316) | (0.0479) | (0.0455) | |
| Operating Cash Flow Per Share | (0.009603) | (0.025) | (0.0908) | (0.33) | (0.48) | (0.5) | |
| Pb Ratio | (43.48) | 16.77 | 11.74 | 14.85 | 20.17 | 21.18 | |
| Free Cash Flow Per Share | (0.009603) | (0.025) | (0.0908) | (0.33) | (0.48) | (0.5) | |
| Roic | 2.54 | (0.0674) | (0.17) | (0.59) | (1.39) | (1.32) | |
| Net Income Per Share | (0.29) | (0.15) | (0.35) | (0.59) | (0.69) | (0.73) | |
| Payables Turnover | 0.013 | 0.005679 | 0.0131 | 0.0164 | 0.1 | 0.11 | |
| Cash Per Share | 5.82E-4 | 2.26 | 2.1 | 1.04 | 0.54 | 0.68 | |
| Pocfratio | (200.22) | (401.83) | (73.38) | (31.66) | (20.86) | (21.91) | |
| Pfcf Ratio | (200.22) | (401.83) | (73.38) | (31.66) | (20.86) | (21.91) | |
| Days Payables Outstanding | 28.1K | 64.3K | 27.8K | 22.3K | 3.6K | 3.4K | |
| Income Quality | 0.0856 | 0.62 | 0.94 | 0.79 | 0.73 | 0.38 | |
| Roe | 2.54 | (0.0674) | (0.17) | (0.58) | (1.33) | (1.26) | |
| Ev To Operating Cash Flow | (200.2) | (376.98) | (67.04) | (29.49) | (19.78) | (20.77) | |
| Pe Ratio | (17.14) | (248.8) | (69.32) | (25.79) | (15.2) | (15.96) | |
| Return On Tangible Assets | (501.14) | (0.065) | (0.17) | (0.57) | (1.27) | (1.34) | |
| Ev To Free Cash Flow | (200.2) | (376.98) | (67.04) | (29.49) | (19.78) | (20.77) | |
| Earnings Yield | (0.0583) | (0.004019) | (0.0144) | (0.0388) | (0.0658) | (0.0691) | |
| Intangibles To Total Assets | 0.74 | 5.66E-4 | 4.63E-4 | 6.68E-4 | 7.71E-4 | 7.32E-4 | |
| Net Debt To E B I T D A | 0.001812 | 15.41 | 5.92 | 1.68 | 0.75 | 0.71 | |
| Current Ratio | 0.004963 | 27.41 | 70.63 | 51.23 | 23.74 | 19.78 | |
| Tangible Book Value Per Share | (0.12) | 2.17 | 2.07 | 1.02 | 0.52 | 0.47 | |
| Graham Number | 0.87 | 2.68 | 4.05 | 3.68 | 2.85 | 1.97 | |
| Shareholders Equity Per Share | (0.11) | 2.18 | 2.07 | 1.02 | 0.52 | 0.47 | |
| Graham Net Net | (0.12) | 2.17 | 2.07 | 1.02 | 0.52 | 0.47 | |
| Enterprise Value Over E B I T D A | (17.16) | (233.65) | (62.63) | (22.75) | (13.75) | (14.43) | |
| Price Earnings Ratio | (17.14) | (248.8) | (69.32) | (25.79) | (15.2) | (15.96) | |
| Price Book Value Ratio | (43.48) | 16.77 | 11.74 | 14.85 | 20.17 | 21.18 | |
| Price Earnings To Growth Ratio | (0.16) | 5.15 | (0.52) | (0.38) | (0.9) | (0.85) | |
| Days Of Payables Outstanding | 28.1K | 64.3K | 27.8K | 22.3K | 3.6K | 3.4K | |
| Price To Operating Cash Flows Ratio | (200.22) | (401.83) | (73.38) | (31.66) | (20.86) | (21.91) | |
| Price To Free Cash Flows Ratio | (200.22) | (401.83) | (73.38) | (31.66) | (20.86) | (21.91) | |
| Effective Tax Rate | (1.0E-6) | 4.47E-4 | 0.005988 | 0.0275 | 0.0316 | 0.0233 | |
| Company Equity Multiplier | (0.0107) | (0.0198) | 1.04 | 1.01 | 1.02 | 1.1 | |
| Return On Capital Employed | 2.54 | (0.0675) | (0.17) | (0.61) | (1.39) | (1.32) | |
| Quick Ratio | 0.004963 | 27.41 | 70.63 | 51.23 | 23.74 | 19.78 |
Currently Active Assets on Macroaxis
When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Return On Assets (0.72) | Return On Equity (1.24) |
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.